On Tuesday, Shares of Keryx Biopharmaceuticals (NASDAQ:KERX), added 1.91% and closed at $6.41 in the last trading session. The last trading range of the stock ranges between $5.82 and $6.65. The company’s Market capitalization is $668.58 million with the total Outstanding Shares of 105.96 million. During the 52-week trading session the minimum price at which share price traded, registered at $2.80 and reached to max level of $7.80. The EPS of company is strolling at -1.56. Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, recently declared that the U.S. Food and Drug Administration (FDA) has approved its application for a second drug product contract manufacturer. Patheon Manufacturing Services LLC of Greenville, North Carolina, a leading global provider of pharmaceutical manufacturing services, is now an FDA approved drug product manufacturer of Auryxia®. With FDA approval of this manufacturer, the company has rebuilt supply and will promptly make Auryxia available to wholesalers.
“We are happy with recently’s approval, as it expands our manufacturing capabilities and capacity,” said Greg Madison, president and chief executive officer of Keryx Biopharmaceuticals. “Getting a second drug product manufacturer approved was an important step to ensuring long-term supply of Auryxia is consistently available to patients.”
Shares of Mallinckrodt PLC (NYSE:MNK), dropped -0.12% and closed at $67.80 in the last trading session. The last trading range of the stock ranges between $65.75 and $68.12. The company’s Market capitalization is $7.52 Billion with the total Outstanding Shares of 107.71 million. During the 52-week trading session the minimum price at which share price traded, registered at $50.90 and reached to max level of $85.83. The EPS of company is strolling at 4.55. Mallinckrodt plc (MNK), a leading global specialty biopharmaceutical company, recently confirmed enrollment of the first patients in the company’s Phase 4 clinical study assessing the efficacy of H.P. Acthar® Gel (repository corticotropin injection) in Systemic Lupus Erythematosus (SLE) patients with persistently active disease. This randomized, double-blind, placebo-controlled trial builds on data from a pilot study of H.P. Acthar Gel in patients with active SLE, recently published online in the journal Lupus Science & Medicine in a manuscript titled “Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomized, controlled pilot study.”